Are there any realistic chances to develop new drugs for asthma?

Drug News and Perspectives

Volumn 19, Issue 4, 2006, Pages 189-200

  Amon, Annette ^b   Pahl, Andreas ^b   Szelenyi, Istvan ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTRAKINCEPT; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; DNA VACCINE; ETANERCEPT; GENISTEIN; GLUCOCORTICOID; HERBACEOUS AGENT; I KAPPA B; IMMUNOSTIMULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; LEVALBUTEROL; MATRIX METALLOPROTEINASE INHIBITOR; MEPOLIZUMAB; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MONOCLONAL ANTIBODY; MONTELUKAST; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHODIESTERASE IV INHIBITOR; PIOGLITAZONE; PRANLUKAST; PROTEIN TYROSINE KINASE INHIBITOR; SALBUTAMOL; UNINDEXED DRUG;

ALTERNATIVE MEDICINE; ASTHMA; BRONCHOSPASM; CANDIDIASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; DRUG TOLERABILITY; HEMIPLEGIA; HOARSENESS; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; POWDER INHALER; RESPIRATORY TRACT INFLAMMATION; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CHEMOKINES; COMPLEMENTARY THERAPIES; GENE THERAPY; HUMANS; IMMUNIZATION; INFLAMMATION MEDIATORS; MATRIX METALLOPROTEINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-TYROSINE KINASES;

EID: 33748951758     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.4.985935     Document Type: Review

References (86)

1. Chiappara, G., Gagliardo, R., Siena, A. et al. Airway remodelling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 2001, 85-93.
2. Carl, J.C., Myers, T.R., Kirchner, H.L., Kercsmar, CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003, 143: 731-6.
3. Henderson, W.R. Jr., Chi, E.Y. and Maliszewski, C.R. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol 2000, 164: 1086-95.
4. Pleskow, W.W., Nelson, H.S., Schaefer, K., Claus, R. and Roach, J.M. Pairwise comparison of levalbuterol versus racemic albuterol in the treatment of moderate-to-severe asthma. Allergy Asthma Proc 2004, 25: 429-36.
5. Cazzola, M., Matera, M.G. and Lotvall, J. Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005, 14: 775-83.
6. Kanniess, F., Cameron, R., Owen, R. and Higgins, M. Indacaterol, a novel alpha2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study. Eur Resp J 2005, 26(Suppl 49): Abst 1729.
7. Leung, D.Y., Spahn, J.D. and Szefler, S.J. Steroid-unresponsive asthma. Semin Respir Crit Care Med 2002, 23: 387-98.
8. Evans, J.M., Barnes, N.C., Zakrzewski, J.T. et al. L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man. Br J Clin Pharmacol 1989, 28: 125-35.
9. Bowton, D.L., Dmitrienko, A.A., Israel, E., Zeiher, B.C. and Sides, G.D. Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma. J Asthma 2005, 42: 65-71.
10. Heuer, H.O. The effects of hetrazepine PAF antagonists in preclinical models of asthma. Agents Actions Suppl 1991, 34: 229-45.
11. Barnes, P.J. Mediators and asthma. Br J Hosp Med 1985, 34: 339-44.
12. Boguniewicz, M., Martin, R.J., Martin, D. et al. The effects of nebulized recombinant interferon-gamma in asthmatic airways. J Allergy Clin Immunol 1995, 95(1 Pt 1): 133-5.
13. Lauw, F.N., Pajkrt, D., Hack, C.E., Kurimoto, M., van Deventer, S.J. and van der Poll, T. Proinflammatory effects of IL-10 during human endotoxemia. J Immunol 2000, 165: 2783-9.
14. Sur, S., Bouchard, P., Holbert, D., Van Scott, M.R. Mucosal IL-12 inhibits airway reactivity to methacholine and respiratory failure in murine asthma. Exp Lung Res 2000, 26: 477-89.
15. Bryan, S.A., O'Connor, B.J., Matti, S. et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356: 2149-53.
16. Casale, T.B., Costa, J.J. and Galli, S.J. TNF alpha is important in human lung allergic reactions. Am J Respir Cell Mol Biol 1996, 15: 35-44.
17. Russo, C., Polosa, R. TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis. Clin Sci 2005, 109: 135-42.
18. Lukacs, N.W., Strieter, R.M., Chensue, S.W., Widmer, M. and Kunkel, S.L. TNF-alpha mediates recruitment of neutrophils and eosinophils during airway inflammation. J Immunol. 1995, 154: 5411-7.
19. Renzetti, L.M., Paciorek, P.M., Tannu, S.A. et al. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J Pharmacol Exp Ther 1996, 278: 847-53.
20. Khalil Saadeh, C., Brown, D., Chumney-Malacara, J. and Crow, J. Infliximab therapy for rheumatoid arthritis (RA) induced significant control of asthma in patients with both RA and asthma or asthma/COPD in addition to improving RA status. J Allergy Clin Immunol 2002, 109: A741.
21. Holgate, S.T. Cytokine and anti-cytokine therapy for the treatment of asthma and allergic disease. Cytokine 2004, 28(4-5): 152-7.
22. Babu, K.S., Arshad, S.H., Howarth, P.H. et al. Soluble tumor necrosis factor alpha (TNF-alpha) receptor (Enbrel) as an effective therapeutic strategy in chronic severe asthma. J Allergy Clin Immunol 2003, 111: S277
23. Howarth, P.H., Babu, K.S., Arshad, H.S. et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005, 60: 1012-8.
24. Rouhani, F.N., Meitin, C.A., Kaler, M., Miskinis-Hilligoss, D., Stylianou, M. and Levine, S.J. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir Med 2005, 99: 1175-82.
25. Keane, J., Gershon, S., Wise, R.P. et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345: 1098-104.
26. Ehlers, S. Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005, 41 Suppl 3: S199-203.
27. Leckie, M.J., ten Brinke, A., Khan, J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000, 356: 2144-8.
28. Flood-Page, P.T., Menzies-Gow, A.N., Kay, A.B. and Robinson, D.S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003, 167: 199-204.
29. Oldhoff, J.M., Darsow, U., Werfel, T. et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005, 60: 693-6.
30. Phipps, S., Flood-Page, P., Menzies-Gow, A., Ong, Y.E. and Kay, A.B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J Invest Dermatol 2004, 122: 1406-12.
31. Kips, J.C., O'Connor, B.J., Langley, S.J. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003, 167: 1655-9.
32. Kay, A.B. and Menzies-Gow, A. Eosinophils and interleukin-5: the debate continues. Am J Respir Crit Care Med 2003, 167: 1586-7.
33. Henderson, W.R., Jr., Chi, E.Y. and Maliszewski, C.R. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J Immunol 2000, 164: 1086-95.
34. Borish, L.C., Nelson, H.S., Lanz, M.J. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160: 1816-23.
35. Borish, L.C., Nelson, H.S., Corren, J. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107: 963-70.
36. Harris, N.L., Peach, R.J. and Ronchese, F. CTLA4-Ig inhibits optimal T helper 2 cell development but not protective immunity or memory response to Nippostrongylus brasiliensis. Eur J Immunol 1999, 29: 311-6.
37. Tomkinson, A., Duez, C., Cieslewicz, G. et al. A murine IL-4 receptor antagonist that inhibits IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001, 166: 5792-800.
38. May R.D., Martin, E.G., Monk, P.D. et al. CAT-354, an IL-13-neutralising human monoclonal antibody, inhibits airways hyperresponsiveness and eosinophilia in a cynomolgus monkey model of allergen challenge. Eur Resp J 2005; 26(Suppl 49): Abst 1587.
39. Rothenberg, M.E., Luster, A.D., Lilly, C.M., Drazen, J.M. and Leder, P. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J Exp Med 1995, 181: 1211-6.
40. Bodor, N. Retrometabolic drug design-novel aspects, future directions. Pharmazie 2001, 56 Suppl 1: S67-74.
41. Bodor, N., Buchwald, P. Designing safer (soft) drugs by avoiding the formation of toxic and oxidative metabolites. Mol Biotechnol 2004, 26: 123-32.
42. Kurucz, I., Toth, S., Nemeth, K. et al. Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166). J Pharmacol Exp Ther 2003, 307: 83-92.
43. Engelstätter, R., Escher, A., Häfner, D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Resp J 2005, 26(Suppl 49): Abst 1738
44. Giembycz, M.A. Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. Curr Opin Pharmacol 2005, 5: 238-244.
45. Lehnart, S.E., Wehrens, X.H., Reiken, S. et al. Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005, 123: 25-35.
46. Karin, M. The NF-kappa B activation pathway: its regulation and role in inflammation and cell survival. Cancer J Sci Am 1998, Suppl 1: S92-9.
47. Gerlag, D.M., Ransone, L., Tak, P.P. et al. The effect of a T cell-specific NF-kappa B inhibitor on in vitro cytokine production and collagen-induced arthritis. J Immunol 2000, 165: 1652-8.
48. Huang, T.J., Adcock, I.M. and Chung, K.F. A novel transcription factor inhibitor, SP100030, inhibits cytokine gene expression, but not airway eosinophilia or hyperresponsiveness in sensitized and allergen-exposed rat. Br J Pharmacol 2001, 134: 1029-36.
49. Poynter, M.E., Cloots, R., van Woerkom, T. et al. NF-kappa B activation in airways modulates allergic inflammation but not hyperresponsiveness. J Immunol 2004, 173: 7003-9.
50. El Bakkouri, K., Wullaert, A., Haegman, M., Heyninck, K. and Beyaert, R. Adenoviral gene transfer of the NF-kappa B inhibitory protein ABIN-1 decreases allergic airway inflammation in a murine asthma model. J Biol Chem 2005, 280: 17938-44.
51. Catley, M.C., Chivers, J.E., Holden, N.S., Barnes, P.J. and Newton, R. Validation of IKK beta as therapeutic target in airway inflammatory disease by adenoviral-mediated delivery of dominant-negative IKK beta to pulmonary epithelial cells. Br J Pharmacol 2005, 145: 114-22.
52. Ziegelbauer, K., Gantner, F., Lukacs, N.W. et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 2005, 145: 178-92.
53. Honda, K., Marquillies, P., Capron, M. and Dombrowicz, D. Peroxisome proliferator-activated receptor gamma is expressed in airways and inhibits features of airway remodeling in a mouse asthma model. J Allergy Clin Immunol 2004, 113: 882-8.
54. Lee, K.S., Park, S.J., Hwang, P.H. et al. PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J 2005, 19: 1033-5.
55. Virag, L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol Res 2005, 52: 83-92.
56. Boulares, A.H., Zoltoski, A.J., Sherif, Z.A., Jolly, P., Massaro, D. and Smulson, M.E. Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma. Am J Respir Cell Mol Biol 2003, 28: 322-9.
57. Suzuki, Y., Masini, E., Mazzocca, C. et al. Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs. J Pharmacol Exp Ther 2004, 311: 1241-8.
58. Virag, L., Bai, P., Bak, I. et al. Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med Sci Monit 2004, 10: BR77-83.
59. Eynott, P.R., Xu, L., Bennett, B.L. et al. Effect of an inhibitor of Jun N-terminal protein kinase, SP600125, in single allergen challenge in sensitized rats. Immunology 2004, 112: 446-53.
60. Chue, S.C., Seow, C.J., Duan, W., Yeo, K.S., Koh, A.H. and Wong, W.S. Inhibitor of p42/44 mitogen-activated protein kinase, but not p 38 MAPK, attenuated antigen challenge of guinea pig airways in vitro. Int Immunopharmacol 2004, 4: 1089-98.
61. Duan, W., Chan, J.H., Wong, C.H., Leung, B.P. and Wong, W.S. Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model. J Immunol 2004, 172: 7053-9.
62. Chialda, L., Zhang, M., Brune, K., Pahl, A. Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. Respir Res 2005, 6: 36.
63. Trifilieff, A., Keller, T.H., Press, N.J. et al. CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol 2005, 144: 1002-10.
64. Berlin, A.A. and Lukacs, N.W. Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 2005, 171: 35-9.
65. Duan, W., Kuo, I.C., Selvarajan, S., Chua, K.Y., Bay, B.H. and Wong, W.S. Anti-inflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am J Respir Crit Care Med 2003, 167: 185-92.
66. Mautino, G., Henriquet, C., Gougat, C. et al. Increased expression of tissue inhibitor of metalloproteinase-1 and loss of correlation with matrix metalloproteinase-9 by macrophages in asthma. Lab Invest 1999, 79: 39-47.
67. Ohno, I., Ohtani, H., Nitta, Y. et al. Eosinophils as a source of matrix metalloproteinase-9 in asthmatic airway inflammation. Am J Respir Cell Mol Biol 1997, 16: 212-9.
68. Wiehler, S., Cuvelier, S.L., Chakrabarti, S. and Patel, K.D. p38 MAP kinase regulates rapid matrix metalloproteinase-9 release from eosinophils. Biochem Biophys Res Commun 2004, 315: 463-70.
69. Gearing, A.J., Beckett, P., Christodoulou, M. et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol 1995, 57: 774-77.
70. Kelly, E.A., Busse, W.W. and Jarjour, N.M. Increased matrix metalloproteinase-9 in the airway after allergen challenge. Am J Respir Crit Care Med 2000, 162(3 Pt 1): 1157-61.
71. Lee, Y.C., Song, C.H., Lee, H.B. et al. A murine model of toluene diisocyanate-induced asthma can be treated with matrix metalloproteinase inhibitor. J Allergy Clin Immunol 2001, 108: 1021-6.
72. Lee, Y.C., Lee, H.B., Rhee, Y.K. and Song, C.H. The involvement of matrix metalloproteinase-9 in airway inflammation of patients with acute asthma. Clin Exp Allergy 2001, 31: 1623-30.
73. Bruce, C. and Thomas, P.S. The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity. Toxicol Appl Pharmacol 2005, 205: 126-32.
74. Blanc, P.D., Trupin, L., Earnest, G., Katz, P.P., Yelin, E.H. and Eisner, M.D. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest 2001, 120: 1461-7.
75. Szelenyi, I. and Brune, K. Unconventional therapies in asthma. Drugs Today 2001, 37: 651-64.
76. Bent, S. and Ko, R. Commonly used herbal medicines in the United States: a review. Am J Med 2004, 116: 478-85.
77. Rahman, I. Oxidative stress and gene transcription in asthma and chronic obstructive pulmonary disease: antioxidant therapeutic targets. Curr Drug Targets Inflamm Allergy 2002, 1: 291-315.
78. Cho, Y.S., Lee, J., Lee, T.H. et al. alpha-Lipoic acid inhibits airway inflammation and hyperresponsiveness in a mouse model of asthma. J Allergy Clin Immunol 2004, 114: 429-35.
79. Wood, L.G., Gibson, P.G. and Garg, M.L. Biomarkers of lipid peroxidation, airway inflammation and asthma. Eur Respir J 2003: 177-86.
80. Szelenyi, I., Brune, K. Unconventional therapies in asthma. Drugs Today 2001, 37: 651-64.
81. Szelenyi, I. and Brune, K. Herbal remedies for asthma treatment: between myth and reality. Drugs Today 2002, 38: 265-303.
82. Nyce, J.W. and Metzger, WJ. DNA antisense therapy for asthma in an animal model. Nature 1997, 385: 721-5.
83. Metzger, W.J. and Nyce, J.W. Oligonucleotide therapy of allergic asthma. J Allergy Clin Immunol 1999, 104(2 Pt 1): 260-6.
84. Karras, J.G., McGraw, K., McKay, R.A. et al. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma. J Immunol 2000. 164: 5409-15.
85. Finotto, S., De Sanctis, G.T., Lehr, H.A. et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001, 193: 1247-60.
86. Szelenyi, I. and Bölcskei, P. Future trends in asthma therapy. Drug News Perspect 1989, 2: 270-7.